Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology
company and drug delivery platform innovator, has submitted a Health Canada
research application for a license to allow in-house research to be conducted
at its Kelowna-based laboratory. A recent article further discussing the
company reads, “Lexaria submitted its research application under Health
Canada’s Cannabis Tracking and Licensing System for the operation of a research
and development (R&D) laboratory to work with cannabinoids within the
company’s new Kelowna head office, now under construction. In fact, Lexaria
will commence experimental work on nicotine formulations, NSAIDs, vitamins and
other bioactive compounds of interest after the completion of this laboratory
facility. … The construction of the new head office and laboratory is advancing
fast. Lexaria expects to occupy the new facility by the end of January 2019.
The company is recruiting more staff to prepare for more wide-ranging
operations. Moreover, Lexaria has taken delivery of specific equipment in a
separate location where it is uniting known nano-emulsification processes with
its DehydraTECH drug delivery platform for enhanced performance
characteristics. This work will also transition to the Kelowna laboratory upon
the facility being operational and licensed.”
To view the full article, visit http://ibn.fm/ufNlO
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented
delivery technology that promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. Lexaria has
multiple patents pending in over 40 countries around the world and has patents
granted in the USA and in Australia for utilization of its DehydraTECH™
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer excellent
growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment